Tags

Type your tag names separated by a space and hit enter

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.
Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.AP

Abstract

BACKGROUND

The efficacy of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine (CAIV-T) against influenza A(H3N2) and B infections in healthy persons is established, but its effectiveness against natural influenza A(H1N1) infection is unknown.

OBJECTIVE

To assess the effectiveness of CAIV-T in healthy children during the 2000-2001 influenza A(H1N1) and B epidemic.

DESIGN

Community-based, nonrandomized, open-label trial from August 1998 through April 2001.

SETTING

Intervention and comparison communities in central Texas.

PARTICIPANTS

Healthy children, aged 1.5 to 18 years, from the intervention communities received a single dose of CAIV-T at least 1 time or more in 1998, 1999, and/or 2000.

MAIN OUTCOME MEASURES

The incidence of medically attended acute respiratory illnesses during the 2000-2001 influenza epidemic was compared in 3794 health plan CAIV-T recipients with age-eligible, health plan nonrecipients in the intervention communities for direct effectiveness (n = 9325), and with those in the 2 comparison communities for total effectiveness (n = 16,264).

RESULTS

The 2281 CAIV-T recipients in 2000 had significant direct protection against medically attended acute respiratory illness of 18% to 20% during the biphasic influenza A(H1N1) and B epidemic, and 17% to 26% during influenza A(H1N1) predominance. The 931 recipients of CAIV-T in 1999 containing influenza A/Beijing/262/95(H1N1) and B/Beijing/184/93-like viruses had persistent heterovariant protection against the 2000-2001 influenza A/New Caledonia/20/99(H1N1) and B/Sichuan/379/99 variants. The 616 recipients of a single CAIV-T dose in 1999 only, including those younger than 5 years with no prior natural exposure to influenza A(H1N1) viruses, showed persistent protection.

CONCLUSION

Healthy children who received CAIV-T in 2000 or 1999 were protected against new variants of influenza A(H1N1) and B in the 2000-2001 influenza epidemic.

Authors+Show Affiliations

Section of Pediatric Infectious Diseases, Department of Pediatrics, Scott & White Memorial Hospital and Clinic, The Texas A&M University System Health Science Center College of Medicine, Temple, 76508, USA. mgaglani@swmail.sw.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14706961

Citation

Gaglani, Manjusha J., et al. "Direct and Total Effectiveness of the Intranasal, Live-attenuated, Trivalent Cold-adapted Influenza Virus Vaccine Against the 2000-2001 Influenza A(H1N1) and B Epidemic in Healthy Children." Archives of Pediatrics & Adolescent Medicine, vol. 158, no. 1, 2004, pp. 65-73.
Gaglani MJ, Piedra PA, Herschler GB, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158(1):65-73.
Gaglani, M. J., Piedra, P. A., Herschler, G. B., Griffith, M. E., Kozinetz, C. A., Riggs, M. W., Fewlass, C., Halloran, M. E., Longini, I. M., & Glezen, W. P. (2004). Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Archives of Pediatrics & Adolescent Medicine, 158(1), 65-73.
Gaglani MJ, et al. Direct and Total Effectiveness of the Intranasal, Live-attenuated, Trivalent Cold-adapted Influenza Virus Vaccine Against the 2000-2001 Influenza A(H1N1) and B Epidemic in Healthy Children. Arch Pediatr Adolesc Med. 2004;158(1):65-73. PubMed PMID: 14706961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. AU - Gaglani,Manjusha J, AU - Piedra,Pedro A, AU - Herschler,Gayla B, AU - Griffith,Melissa E, AU - Kozinetz,Claudia A, AU - Riggs,Mark W, AU - Fewlass,Charles, AU - Halloran,M Elizabeth, AU - Longini,Ira M,Jr AU - Glezen,W Paul, PY - 2004/1/7/pubmed PY - 2004/2/27/medline PY - 2004/1/7/entrez SP - 65 EP - 73 JF - Archives of pediatrics & adolescent medicine JO - Arch Pediatr Adolesc Med VL - 158 IS - 1 N2 - BACKGROUND: The efficacy of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine (CAIV-T) against influenza A(H3N2) and B infections in healthy persons is established, but its effectiveness against natural influenza A(H1N1) infection is unknown. OBJECTIVE: To assess the effectiveness of CAIV-T in healthy children during the 2000-2001 influenza A(H1N1) and B epidemic. DESIGN: Community-based, nonrandomized, open-label trial from August 1998 through April 2001. SETTING: Intervention and comparison communities in central Texas. PARTICIPANTS: Healthy children, aged 1.5 to 18 years, from the intervention communities received a single dose of CAIV-T at least 1 time or more in 1998, 1999, and/or 2000. MAIN OUTCOME MEASURES: The incidence of medically attended acute respiratory illnesses during the 2000-2001 influenza epidemic was compared in 3794 health plan CAIV-T recipients with age-eligible, health plan nonrecipients in the intervention communities for direct effectiveness (n = 9325), and with those in the 2 comparison communities for total effectiveness (n = 16,264). RESULTS: The 2281 CAIV-T recipients in 2000 had significant direct protection against medically attended acute respiratory illness of 18% to 20% during the biphasic influenza A(H1N1) and B epidemic, and 17% to 26% during influenza A(H1N1) predominance. The 931 recipients of CAIV-T in 1999 containing influenza A/Beijing/262/95(H1N1) and B/Beijing/184/93-like viruses had persistent heterovariant protection against the 2000-2001 influenza A/New Caledonia/20/99(H1N1) and B/Sichuan/379/99 variants. The 616 recipients of a single CAIV-T dose in 1999 only, including those younger than 5 years with no prior natural exposure to influenza A(H1N1) viruses, showed persistent protection. CONCLUSION: Healthy children who received CAIV-T in 2000 or 1999 were protected against new variants of influenza A(H1N1) and B in the 2000-2001 influenza epidemic. SN - 1072-4710 UR - https://www.unboundmedicine.com/medline/citation/14706961/Direct_and_total_effectiveness_of_the_intranasal_live_attenuated_trivalent_cold_adapted_influenza_virus_vaccine_against_the_2000_2001_influenza_A_H1N1__and_B_epidemic_in_healthy_children_ L2 - https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/archpedi.158.1.65 DB - PRIME DP - Unbound Medicine ER -